Showing results (71-80 of 443) with videos related to
Sort By:
Pageof 45
Molecular Cancer Therapeutics|December 14, 2002
Characterization of overlapping XAGE-1 transcripts encoding a cancer testis antigen expressed in lung, breast, and other types of cancersKristi A Egland, Vasantha Kumar, Paul Duray, et al.Molecular Cancer Therapeutics|February 22, 2012
Mesothelin-targeted agents in clinical trials and in preclinical developmentRonan J Kelly, Elad Sharon, Ira Pastan, et al.Leukemia & Lymphoma|October 10, 2009
Approach to the patient after relapse of hairy cell leukemiaRobert J Kreitman, David J P Fitzgerald, Ira PastanJournal of Immunological Methods|June 10, 2015
Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin ARonit Mazor, Chin-Hsien Tai, Byungkook Lee, et al.Scientific Reports|June 27, 2015
Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro resultsEmily Mason-Osann, Kevin Hollevoet, Gerhard Niederfellner, et al.Cancer Research|August 5, 2008
Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activityXing Du, Richard Beers, David J Fitzgerald, et al.Plos One|October 25, 2014
Effect of antigen shedding on targeted delivery of immunotoxins in solid tumors from a mathematical modelYoungshang Pak, Ira Pastan, Robert J Kreitman, et al.Leukemia & Lymphoma|April 21, 2011
Immunotoxins with decreased immunogenicity and improved activityIra Pastan, Masanori Onda, John Weldon, et al.Clinical & Developmental Immunology|March 9, 2012
Toxin-based targeted therapy for malignant brain tumorsVidyalakshmi Chandramohan, John H Sampson, Ira Pastan, et al.Annual Review of Medicine|October 25, 2006
Immunotoxin treatment of cancerIra Pastan, Raffit Hassan, David J FitzGerald, et al.Pageof 45